Acurx Pharmaceuticals LLC, a clinical stage, privately-held biopharmaceutical company focused on developing new antibiotics for difficult-to-treat bacterial infections, announced yesterday that it has received Fast Track designation from the United States Food and Drug Administration (FDA) for ACX-362E, an investigational new treatment for Clostridium difficile Infection (CDI).
The product is a novel, oral antibiotic that recently entered Phase one development. It is the first of a novel class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections.
David P Luci, co-founder & managing partner of Acurx, said, 'FDA's granting of Fast Track designation for our lead antibiotic program validates our business model, which includes a pipeline of DNA polymerase IIIC Inhibitors we are currently developing to treat other resistant bacterial infections.'
Acurx intends to complete the drug's Phase 1 clinical trial in the second quarter of 2019 and is planning to advance ACX-362E into a Phase 2 clinical trial in the fourth quarter of 2019.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT